That resource is reserved for health professionals and professionals using DM-DIV

This content is promotional.


The mAbXmise quantification kits are intended to monitor the concentration of therapeutic monoclonal antibodies (mAbs) in samples from patients treated with these mAbs. The kit is a quantitative assay. The test can be performed on plasma (EDTA, heparin or citrate collection tubes) and serum. Assay results are intended to be used by healthcare professionals. Before use, it is important to carefully read the instructions provided with the product.


This space contains information on medical devices, the use of which is reserved for healthcare professionals. In application of the law of December 29, 2011 relating to the strengthening of health security, I certify that I am a health professional and therefore be authorized to access this information.


mAbXmise monoclonal antibodies quantification kits are In Vitro Diagnostic Medical Devices for laboratory professional use and CE-IVD labeled for Europe by BSI. Assay results are intended to be used by healthcare professionals. The kits are designed to perform absolute quantification by LC-MS (Liquid Chromatography – Mass spectrometry) of specific therapeutic monoclonal antibodies (mAbs) in a patient sample. Assay results are intended to be used by healthcare professionals. Before use, it is important to carefully read the instructions provided with the product. The products are non-refundable. The mAbXmise Kit described has not been cleared by any regulatory entity for diagnostic purposes outside of Europe. Proteomics mAbXmise Kits are not available for sale in all countries.


I am a healthcare professional


Validate


Close window if you are not a healthcare professional

 

Close menu

Contact

Services

Quantification of therapeutic monoclonal
antibodies in complex matrices

Monoclonal antibodies (mAbs) are increasingly being used for treatment of a variety of diseases leading to an increasing interest into researching how the amount of these biotherapeutics relates to response, potential side effects and cost effectiveness.

Promise approach & developments

For clinical research scientists, Promise Proteomics has developed a kit-based approach comprising a sample preparation of both reagents and consumables combined with optimised LC-MS protocols to supply reproducible workflows that can be easily implemented and operated.

Unlike immunoassays which require mAb specific reagents, our methodology benefits from the use of stable isotopically labelled, the ideal internal standards, combined with an LC-MS read out that provides optimal specificity and rapid quantitation as well as enabling multiplex analysis of different mAbs.

The feasibility of Promise’s approach has been tested within clinical research studies demonstrating the reliability and robustness of the overall workflow. Published data from these studies has highlighted how our technology offers distinct advantages over immunoassays for quantification of Mab drugs.